Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukaemia

Cancer Letters

Volumn 199, Issue 2, 2003, Pages 185-192

  Levy Nissenbaum, Orlev ^a   Sagi Assif, Orit ^a   Raanani, Pia ^a,b   Avigdor, Abraham ^a,b   Ben Bassat, Isaac ^a,b   Witz, Isaac P ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Acute leukemia; Acute myelogenous leukemia; cDNA microarray; Dual specificity phosphatases (DUSP); Gene expression; MAPK; PYST2

Indexed keywords

ISOENZYME; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLOOD BANK; BLOOD DONOR; BONE MARROW CELL; CANCER CELL CULTURE; CANCER GENETICS; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; MONONUCLEAR CELL; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0142091663     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00352-5     Document Type: Article

References (37)

1. Drexler H.G., Borkhardt A., Janssen J.W. Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction. Leuk. Lymphoma. 19:1995;359-380.
2. Biondi A., Rambaldi A. Molecular diagnosis and monitoring of acute myeloid leukemia. Leuk. Res. 20:1996;801-807.
3. Pakkala S., Knuutila S., Helminen P., Ruutu T., Saarinen U.M., Peltonen L. DNA-fingerprint changes compared to karyotypes in acute leukemia. Leukemia. 4:1990;866-870.
4. Sievers E.L. Clinical studies of new 'biologic' approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates. Curr. Opin. Oncol. 12:2000;30-35.
5. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 286:1999;531-537.
6. Mills K.I. Differential display as an approach to study differentiation and differentiation therapy in AML. Hematol. Oncol. 18:2000;129-140.
7. Watson A., Mazumder A., Stewart M., Balasubramanian S. Technology for microarray analysis of gene expression. Curr. Opin. Biotechnol. 9:1998;609-614.
8. Khan J., Bittner M.L., Chen Y., Meltzer P.S., Trent J.M. DNA microarray technology: the anticipated impact on the study of human disease. Biochim. Biophys. Acta. 1423:1999;M17-M28.
9. Rew D.A. DNA microarray technology in cancer research. Eur. J. Surg. Oncol. 27:2001;504-508.
10. Levy-Nissenbaum O., Sagi-Assif O., Raanani P., Avigdor A., Ben-Bassat I., Witz I. cDNA microarray analysis reveals an over expression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. Meth. Enzymol. 2003;. in press.
11. Dowd S., Sneddon A.A., Keyse S.M. Isolation of the human genes encoding the pyst1 and Pyst2 phosphatases: characterization of Pyst2 as a cytosolic dual-specificity MAP kinase phosphatase and its catalytic activation by both MAP and SAP kinases. J. Cell Sci. 111:1998;3389-3399.
12. Muda M., Boschert U., Smith A., Antonsson B., Gillieron C., Chabert C., et al. Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4. J. Biol. Chem. 272:1997;5141-5151.
13. Groom L.A., Sneddon A.A., Alessi D.R., Dowd S., Keyse S.M. Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO J. 15:1996;3621-3632.
14. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H., et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br. J. Haematol. 87:1994;746-754.
15. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51:1982;189-199.
16. Kerkhofs H., Hermans J., Haak H.L., Leeksma C.H. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br. J. Haematol. 65:1987;73-81.
17. Ribera J.M., Cervantes F., Rozman C. A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. Br. J. Haematol. 65:1987;307-311.
18. Eshel R., Zanin A., Kapon D., Sagi-Assif O., Brakenhoff R., van Dongen G., et al. Human Ly-6 antigen E48 (Ly-6D) regulates important interaction parameters between endothelial cells and head-and-neck squamous carcinoma cells. Int. J. Cancer. 98:2002;803-810.
19. Islam L.N., Wilkinson P.C. Evaluation of methods for isolating human peripheral blood monocytes. Studies on chemotactic locomotion and other functional characteristics. J. Immunol. Meth. 121:1989;75-84.
20. Baer M.R., Stewart C.C., Dodge R.K., Leget G., Sule N., Mrozek K., Schiffer C.A., et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 97:2001;3574-3580.
21. Kaleem Z., White G. Diagnostic criteria for minimally differentiated acute myeloid leukemia (AML-M0). Evaluation and a proposal. Am. J. Clin. Pathol. 115:2001;876-884.
22. Hardie D.G. Roles of protein kinases and phosphatases in signal transduction. Symp. Soc. Exp. Biol. 44:1990;241-255.
23. Graves J.D., Krebs E.G. Protein phosphorylation and signal transduction. Pharmacol. Ther. 82:1999;111-121.
24. Besson A., Robbins S.M., Yong V.W. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur. J. Biochem. 263:1999;605-611.
25. Galaktionov K., Lee A.K., Eckstein J., Draetta G., Meckler J., Loda M., et al. CDC25 phosphatases as potential human oncogenes. Science. 269:1995;1575-1577.
26. Wu W., Fan Y.H., Kemp B.L., Walsh G., Mao L. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 58:1998;4082-4085.
27. Nilsson I., Hoffmann I. Cell cycle regulation by the Cdc25 phosphatase family. Prog. Cell Cycle Res. 4:2000;107-114.
28. Biethahn S., Alves F., Wilde S., Hiddemann W., Spiekermann K. Expression of granulocyte colony-stimulating factor- and granulocyte- macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Exp. Hematol. 27:1999;885-894.
29. Beghini A., Ripamonti C.B., Peterlongo P., Roversi G., Cairoli R., Morra E., et al. RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia. Hum. Mol. Genet. 9:2000;2297-2304.
30. Nishikawa M., Yamamoto M., Watanabe Y., Kita K., Shiku H. Clinical significance of low protein phosphatase-1 activity of blasts in acute myelogenous leukemia with high white cell counts. Int. J. Oncol. 18:2001;559-565.
31. Yamamoto M., Suzuki Y., Kihira H., Miwa H., Kita K., Nagao M., et al. Expressions of four major protein Ser/Thr phosphatases in human primary leukemic cells. Leukemia. 13:1999;595-600.
32. Krystal G., Damen J.E., Helgason C.D., Huber M., Hughes M.R., Kalesnikoff J., et al. SHIPs ahoy. Int. J. Biochem. Cell Biol. 31:1999;1007-1010.
33. Dahia P.L. PTEN, unique tumor suppressor gene. Endocr. Relat. Cancer. 7:2000;115-129.
34. Sano K., Hayakawa A., Piao J.H., Kosaka Y., Nakamura H. Novel SH3 protein encoded by the AF3p21 gene is fused to the mixed lineage leukemia protein in a therapy-related leukemia with t(3;11) (p21;q23). Blood. 95:2000;1066-1068.
35. Shi G., Weh H.J., Martensen S., Seeger D., Hossfeld D.K. 3p21 is a recurrent treatment-related breakpoint in myelodysplastic syndrome and acute myeloid leukemia. Cytogenet. Cell Genet. 74:1996;295-299.
36. Johansson B., Billstrom R., Kristoffersson U., Akerman M., Garwicz S., Ahlgren T., et al. Deletion of chromosome arm 3p in hematologic malignancies. Leukemia. 11:1997;1207-1213.
37. Parsons R. Phosphatases and tumorigenesis. Curr. Opin. Oncol. 10:1998;88-91.